Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

HER2DX impacts clinical management in stage I-III HER2-positive BC by supporting treatment adjustments, enhancing physician confidence, maintaining pCR rates, and reducing health care costs.

Authors

Institutions

Publication Details

Journal
ESMO Real World Data and Digital Oncology
Published
2025-03-07
DOI
https://doi.org/10.1016/j.esmorw.2025.100123
Citations
9
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
9.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

Pedro Jares, T. Pascual, Bárbara Adamo, S. Marín-Liébana et al.
9 citations
ESMO Real World Data and Digital Oncology
HER2/EGFR in Cancer Research
9.41
article

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

Pedro Jares, T. Pascual, Bárbara Adamo, S. Marín-Liébana, M.A. Rezqallah Aron, F. Schettini, Esther Carcelero, Fara Brasó‐Maristany, Juan Miguel Cejalvo, Pablo Rivera, Begoña Bermejo, R Gómez-Bravo, María Dolores Torregrosa, Guillermo Villacampa, Antonio Llombart‐Cussac, Ana Santaballa, Marta Tapia, Cristina Hernándo, E. Hernández-Illán, Benjamín Walbaum, C. Saura, Ana Isabel Martínez-Puchol, L. Paré, A. Lluch, Isabel García-Fructuoso, Athanasios Pouptsis, Esther Sanfeliu, Vega Iranzo, Santiago Escrivá-de-Romaní, Núria Chic, Patricia Villagrasa, Iris Garrido‐Cano, Mercedes Marín‐Aguilera, Montserrat Muñoz-Mateu, Aleix Prat, Elia Seguí, María Teresa Martínez, Joan Anton Puig‐Butillé, Octavio Burgués, C. Tébar, A. Magro, Laura Palomar, William Buckingham, O. Martínez-Sáez, B. Conte
article en
9 citations

Abstract

HER2DX impacts clinical management in stage I-III HER2-positive BC by supporting treatment adjustments, enhancing physician confidence, maintaining pCR rates, and reducing health care costs.

ESMO Real World Data and Digital OncologyVol. 8
Universitat de València (ES), Peter MacCallum Cancer Centre (AU), Hospital Universitari i Politècnic La Fe (ES), Hospital de La Ribera (ES), Hospital Clínico Universitario de Valencia (ES), Vall d'Hebron Institut de Recerca (ES), Center for Cancer and Blood Disorders (US), Hospital Quirónsalud Barcelona (ES), Hospital Clínic de Barcelona (ES), Hospital Arnau de Vilanova (ES), Vall d'Hebron Hospital Universitari (ES), Hospital General Universitario De Valencia (ES), Hospital de Sagunto (ES), Oryzon Genomics (Spain) (ES), Hospital Comarcal de Inca (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Vall d'Hebron Institute of Oncology (ES), Universitat de Barcelona (ES)
Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Albert Einstein Cancer Center, Les Laboratories Pierre Fabre, Veracyte, Seagen, Fundación Científica Asociación Española Contra el Cáncer, Eisai, Instituto de Salud Carlos III, Daiichi Sankyo Europe
Gender equality
Openalex Percentile: Top 2%
HER2/EGFR in Cancer Research
9.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.